CR11854A - Compuestos de piridina - Google Patents

Compuestos de piridina

Info

Publication number
CR11854A
CR11854A CR11854A CR11854A CR11854A CR 11854 A CR11854 A CR 11854A CR 11854 A CR11854 A CR 11854A CR 11854 A CR11854 A CR 11854A CR 11854 A CR11854 A CR 11854A
Authority
CR
Costa Rica
Prior art keywords
compounds
medicaments
piridine
piridine compounds
humans
Prior art date
Application number
CR11854A
Other languages
English (en)
Inventor
Christophe Barlaam Bernard
Michael Foote Kevin
Ple Patrick
David Jones Clifford
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR11854A publication Critical patent/CR11854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención se relaciona con compuestos que inhiben la función de la quinasa de adhesión focal, con los procesos para prepararlos, las composiciones farmacéuticas que los contienen como ingrediente activo, su uso como medicamentos y su uso en la fabricación de medicamentos para tratar enfermedades como el cáncer en animales de sangre caliente como el ser humano.
CR11854A 2008-06-17 2010-12-17 Compuestos de piridina CR11854A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7305508P 2008-06-17 2008-06-17

Publications (1)

Publication Number Publication Date
CR11854A true CR11854A (es) 2011-02-25

Family

ID=40896110

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11854A CR11854A (es) 2008-06-17 2010-12-17 Compuestos de piridina

Country Status (18)

Country Link
US (1) US8569298B2 (es)
EP (1) EP2303861B1 (es)
JP (1) JP5551689B2 (es)
KR (1) KR101695501B1 (es)
CN (1) CN102124000B (es)
AU (1) AU2009261764B2 (es)
BR (1) BRPI0914927B8 (es)
CA (1) CA2726508C (es)
CR (1) CR11854A (es)
DO (1) DOP2010000390A (es)
EA (1) EA020807B1 (es)
EC (1) ECSP10010695A (es)
ES (1) ES2472323T3 (es)
HK (1) HK1155170A1 (es)
IL (1) IL209727A0 (es)
MX (1) MX2010014057A (es)
WO (1) WO2009153589A1 (es)
ZA (1) ZA201100388B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140155410A1 (en) * 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
WO2010068947A2 (en) * 2008-12-12 2010-06-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nuclear export inhibitors of topoisomerase ii alpha
AU2010276537B2 (en) 2009-07-27 2015-04-16 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
MX340819B (es) 2010-06-29 2016-07-26 Poniard Pharmaceuticals Inc * Formulacion oral de inhibidores de quinasa.
EP2588476A4 (en) * 2010-06-30 2014-07-23 Verastem Inc SYNTHESIS AND USE OF KINASE INHIBITORS
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
BR112013018565A2 (pt) * 2011-01-26 2016-09-27 Univ Texas combinações
ES2691673T3 (es) 2011-02-17 2018-11-28 Cancer Therapeutics Crc Pty Limited Inhibidores de Fak
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
TWI510480B (zh) 2011-05-10 2015-12-01 Gilead Sciences Inc 充當離子通道調節劑之稠合雜環化合物
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
US9365556B2 (en) 2012-03-16 2016-06-14 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
AP2016009605A0 (en) * 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
US9442005B2 (en) 2014-07-30 2016-09-13 Corning Optical Communications LLC Non-contact methods of measuring insertion loss in optical fiber connectors
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
CN108289892B (zh) 2015-06-29 2021-11-23 维瑞斯特姆股份有限公司 治疗组合物、组合和使用方法
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
EP3758491A1 (en) 2018-02-28 2021-01-06 Basf Se Use of pyrazole propargyl ethers as nitrification inhibitors
JP7444780B2 (ja) 2018-02-28 2024-03-06 ビーエーエスエフ ソシエタス・ヨーロピア 硝化阻害剤としてのｎ－官能化アルコキシピラゾール化合物の使用
AU2019236402A1 (en) 2018-03-12 2020-10-01 Assistance Publique-Hôpitaux De Paris (Aphp) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
CN114793434A (zh) * 2019-10-18 2022-07-26 加利福尼亚大学董事会 作为用于治疗病原性血管病症的药剂的3-苯基磺酰基-喹啉衍生物
CA3219128A1 (en) 2021-05-21 2022-11-24 Barbara Nave Use of an n-functionalized alkoxy pyrazole compound as nitrification inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DE10336184A1 (de) 2003-08-07 2005-02-24 Bayer Materialscience Ag Neue Katalysatoren für die selektive Isocyanatdimerisierung
MY147449A (en) * 2003-08-15 2012-12-14 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
MXPA06015170A (es) 2004-06-21 2007-08-21 Pharmacia & Upjohn Co Llc Procedimiento para aumentar la cantidad de hueso.
GB0419161D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419160D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
JP5208516B2 (ja) 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
US8722884B2 (en) * 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EA014551B1 (ru) 2005-12-21 2010-12-30 Пфайзер Продактс Инк. Пиримидиновые производные для лечения аномального клеточного роста
EP2091918B1 (en) 2006-12-08 2014-08-27 Irm Llc Compounds and compositions as protein kinase inhibitors
ES2485040T3 (es) * 2007-03-16 2014-08-12 The Scripps Research Institute Inhibidores de cinasa de adhesión focal
EP2170830B1 (en) * 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
JP2011512413A (ja) * 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン

Also Published As

Publication number Publication date
AU2009261764B2 (en) 2013-01-10
CA2726508C (en) 2016-06-07
EA201100032A1 (ru) 2012-01-30
DOP2010000390A (es) 2011-01-15
JP2011524411A (ja) 2011-09-01
US8569298B2 (en) 2013-10-29
BRPI0914927B1 (pt) 2020-10-06
WO2009153589A1 (en) 2009-12-23
EP2303861A1 (en) 2011-04-06
ES2472323T3 (es) 2014-06-30
CN102124000B (zh) 2014-09-17
EP2303861B1 (en) 2014-04-23
CN102124000A (zh) 2011-07-13
IL209727A0 (en) 2011-02-28
US20110166139A1 (en) 2011-07-07
JP5551689B2 (ja) 2014-07-16
BRPI0914927B8 (pt) 2021-05-25
HK1155170A1 (en) 2012-05-11
EA020807B1 (ru) 2015-01-30
MX2010014057A (es) 2011-03-21
ZA201100388B (en) 2011-10-26
CA2726508A1 (en) 2009-12-23
KR20110023884A (ko) 2011-03-08
KR101695501B1 (ko) 2017-01-11
BRPI0914927A2 (pt) 2017-06-20
AU2009261764A1 (en) 2009-12-23
ECSP10010695A (es) 2011-01-31

Similar Documents

Publication Publication Date Title
CR11854A (es) Compuestos de piridina
CO6721010A2 (es) Antagonistas de mdm2 de espiro-oxindol
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
UY30282A1 (es) Compuestos quimicos
CR20110610A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
UY33890A (es) Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
CR20130432A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
ECSP099451A (es) Compuestos de urea policíclicos antibacterianos
CO6640285A2 (es) 5-alquinil-pirimidinas
UY32383A (es) Dionas cíclicas herbicidamente activas, derivados, procesos para su preparación composiciones que las comprenden y usos de las mismas
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
DOP2015000170A (es) Compuestos químicos
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
UY31141A1 (es) Compuestos de piperidina y sus usos
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
DOP2010000374A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY30880A1 (es) 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)